Young Investigator Award Session - Heart40Targeting the miRNA-106b-25 cluster as a potential regenerative therapeutic approach for myocardial injury41An allogeneic bioengineered myocardial graft limits infarct size and improves cardiac function: pre-clinical study in the porcine myocardial infarction model42Phosphoinositide 3-kinase gamma inhibition protects against anthracycline-induced cardiomyopathy by boosting cardiac autophagy43Functional screening of microRNAs identifies miR-22 as a regulator of cardiac autophagy and aging44Functional defects and molecular mechanisms of left ventricular non-compaction in nkx2.5 mutant mice45PITX2 modulates atrial membrane potential, potentiating the antiarrhythmic effects of sodium channel blockers

Autor: F Syeda, THM Nguyen, S K Gupta, MC Li, I Perea Gil, E Dirkx, A Raso, L Braga, L Zentilin, S Zacchigna, M Giacca, LJ De Windt, C Prat-Vidal, C Galvez-Monton, S Roura, A Llucia-Valldeperas, C Soler-Botija, I Diaz-Guemes, V Crisostomo, FM Sanchez-Margallo, A Bayes-Genis, J Cimino, MC De Santis, N Pianca, S Sciarretta, M Sandri, T Zaglia, M Mongillo, E Hirsch, A Ghigo, C Bauters, P De Groote, A Foinquinos, R Boon, S Batkai, F Pinet, T Thum, C Choquet, F Kober, M Bernard, RG Kelly, L Miquerol, N Lalevee, A Holmes, T Yu, S Tull, S Kuhlmann, D Pavlovic, D Betney, G Riley, JP Kucera, F Jousset, J De Groot, S Rohr, N Brown, L Fabritz, P Kirchhof

Publikováno v: Cardiovascular Research. 111:S8-S9

La LVNC est une cardiomyopathie rare, caracterisee par une hypertrabeculation et de profonds replis du ventricule gauche. A ce jour, nous ne savons toujours pas si la LVNC resulte d'un defaut se produisant durant le developpement cardiaque et si sa g

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1f350229c9fdc78d2e2798a326d0bf5d
https://doi.org/10.1093/cvr/cvw139

The IMproving Preclinical Assessment of Cardioprotective Therapies (IMPACT): multicenter pig study on the effect of ischemic preconditioning.

Autor: Kleinbongard P; Institute for Pathophysiology, West German Heart and Vascular Center, University of Essen Medical School, University of Duisburg-Essen, Hufelandstr. 55, 45122, Essen, Germany. petra.kleinbongard@uk-essen.de., Arriola CG; Centro Nacional de Investigaciones Cardiovasculares Carlos III, CIBER de Enfermedades Cardiovasculares (CIBERCV), Melchor Fernández Almagro 9, 28029, Madrid, Spain. carlos.galan@cnic.es., Badimon L; Research Institute Hospital de La Santa Creu I Sant Pau-IIB Sant Pau, and CIBER Enfermedades Cardiovasculares, Barcelona, Spain., Crisostomo V; Cardiovascular Area, Jesús Usón Minimally Invasive Surgery Centre (CCMIJU), Cáceres, Spain.; CIBER de Enfermedades Cardiovasculares (CIBERCV), RICORS-TERAV Network, ISCIII, Madrid, Spain., Giricz Z; Cardiovascular and Metabolic Research Group, Department of Pharmacology and Pharmacotherapy, Semmelweis University, Budapest, Hungary.; Pharmahungary Group, Szeged, Hungary., Gyöngyösi M; Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, 1090, Vienna, Austria., Heusch G; Institute for Pathophysiology, West German Heart and Vascular Center, University of Essen Medical School, University of Duisburg-Essen, Hufelandstr. 55, 45122, Essen, Germany., Ibanez B; Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain., Kiss A; Ludwig Boltzmann Institute for Cardiovascular Research at the Center for Biomedical Research and Translational Surgery, Medical University of Vienna, Vienna, Austria., de Kleijn DPV; Department of Vascular Surgery, University Medical Center Utrecht, Utrecht, The Netherlands., Podesser BK; Ludwig Boltzmann Institute for Cardiovascular Research at the Center for Biomedical Research and Translational Surgery, Medical University of Vienna, Vienna, Austria., Carracedo RR; Unidad de Investigación Cardiovascular, Departamento de Cardiología, Hospital Ramón y Cajal (IRYCIS), Universidad Francisco de Vitoria, Madrid, Spain., Rodríguez-Sinovas A; Cardiovascular Diseases Research Group, Department of Cardiology, Vall d'Hebron Institut de Recerca (VHIR), Hospital Universitari Vall d'Hebron, Barcelona, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III (ISCIII), Madrid, Spain., Ruiz-Meana M; Cardiovascular Diseases Research Group, Department of Cardiology, Vall d'Hebron Institut de Recerca (VHIR), Hospital Universitari Vall d'Hebron, Barcelona, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III (ISCIII), Madrid, Spain., Sanchez Margallo FM; CIBER de Enfermedades Cardiovasculares (CIBERCV), RICORS-TERAV Network, ISCIII, Madrid, Spain.; Jesús Usón Minimally Invasive Surgery Centre (CCMIJU), Cáceres, Spain., Vilahur G; Research Institute Hospital de La Santa Creu I Sant Pau-IIB Sant Pau, and CIBER Enfermedades Cardiovasculares, Barcelona, Spain., Zamorano JL; University Hospital Ramon Y Cajal, Madrid, Spain., Zaragoza C; Unidad de Investigación Cardiovascular, Departamento de Cardiología, Hospital Ramón y Cajal (IRYCIS), Universidad Francisco de Vitoria, Madrid, Spain., Ferdinandy P; Pharmahungary Group, Szeged, Hungary. peter.ferdinandy@pharmahungary.com.; Department of Pharmacology and Pharmacotherapy, Semmelweis University, Nagyvárad Tér 4, Budapest, 1089, Hungary. peter.ferdinandy@pharmahungary.com.; Center for Pharmacology and Drug Research and Development, Semmelweis University, Budapest, Hungary. peter.ferdinandy@pharmahungary.com., Hausenloy DJ; Cardiovascular and Metabolic Disorders Program, Duke-NUS Medical School, 8 College Road, Singapore, 169857, Singapore. derek.hausenloy@duke-nus.edu.sg.; National Heart Research Institute Singapore, National Heart Centre, Singapore, Singapore. derek.hausenloy@duke-nus.edu.sg.; Yong Loo Lin School of Medicine, National University Singapore, Singapore, Singapore. derek.hausenloy@duke-nus.edu.sg.; The Hatter Cardiovascular Institute, University College London, London, UK. derek.hausenloy@duke-nus.edu.sg.

Publikováno v: Basic research in cardiology [Basic Res Cardiol] 2024 Dec; Vol. 119 (6), pp. 893-909. Date of Electronic Publication: 2024 Oct 18.

Biopolymers for Tissue Engineering: Crosslinking, Printing Techniques, and Applications.

Autor: Patrocinio D; CCMIJU, Bioengineering and Health Technologies, Jesus Usón Minimally Invasive Surgery Center, 10071 Cáceres, Spain., Galván-Chacón V; CCMIJU, Bioengineering and Health Technologies, Jesus Usón Minimally Invasive Surgery Center, 10071 Cáceres, Spain., Gómez-Blanco JC; CCMIJU, Bioengineering and Health Technologies, Jesus Usón Minimally Invasive Surgery Center, 10071 Cáceres, Spain., Miguel SP; CPIRN-IPG, Center of Potential and Innovation of Natural Resources, Polytechnic of Guarda, 6300-559 Guarda, Portugal.; CICS-UBI, Health Science Research Center, University of Beira Interior, 6201-506 Covilhã, Portugal., Loureiro J; CPIRN-IPG, Center of Potential and Innovation of Natural Resources, Polytechnic of Guarda, 6300-559 Guarda, Portugal., Ribeiro MP; CPIRN-IPG, Center of Potential and Innovation of Natural Resources, Polytechnic of Guarda, 6300-559 Guarda, Portugal.; CICS-UBI, Health Science Research Center, University of Beira Interior, 6201-506 Covilhã, Portugal., Coutinho P; CPIRN-IPG, Center of Potential and Innovation of Natural Resources, Polytechnic of Guarda, 6300-559 Guarda, Portugal.; CICS-UBI, Health Science Research Center, University of Beira Interior, 6201-506 Covilhã, Portugal., Pagador JB; CCMIJU, Bioengineering and Health Technologies, Jesus Usón Minimally Invasive Surgery Center, 10071 Cáceres, Spain.; CIBER CV, Centro de Investigación Biomédica en Red-Enfermedades Cardiovasculares, 28029 Madrid, Spain., Sanchez-Margallo FM; CIBER CV, Centro de Investigación Biomédica en Red-Enfermedades Cardiovasculares, 28029 Madrid, Spain.; Scientific Direction, Jesus Usón Minimally Invasive Surgery Center, 10071 Cáceres, Spain.; TERAV/ISCIII, Red Española de Terapias Avanzadas, Instituto de Salud Carlos III (RICORS, RD21/0017/0029), 28029 Madrid, Spain.

Publikováno v: Gels (Basel, Switzerland) [Gels] 2023 Nov 10; Vol. 9 (11). Date of Electronic Publication: 2023 Nov 10.

Personalized tissue-engineered veins - long term safety, functionality and cellular transcriptome analysis in large animals.

Autor: Österberg K; Sahlgrenska Academy, Institution of Medicine, Wallenberg Laboratory, Department of Molecular and Clinical Medicine, Blå Stråket 5 B, 41345 Gothenburg, Sweden., Bogestål Y; RISE Research Institutes of Sweden, Methodology, Textile and Medical Device, Brinellgatan 4, 50462 Borås, Sweden. Joakim.hakansson@ri.se., Jenndahl L; VERIGRAFT AB, Arvid Wallgrensbacke 20, 41346, Göteborg, Sweden., Gustafsson-Hedberg T; VERIGRAFT AB, Arvid Wallgrensbacke 20, 41346, Göteborg, Sweden., Synnergren J; Systems Biology Research Center, School of Bioscience, University of Skövde, 54128 Skövde, Sweden.; Gothenburg University, Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, 41345 Gothenburg, Sweden., Holmgren G; Systems Biology Research Center, School of Bioscience, University of Skövde, 54128 Skövde, Sweden., Bom E; RISE Research Institutes of Sweden, Methodology, Textile and Medical Device, Brinellgatan 4, 50462 Borås, Sweden. Joakim.hakansson@ri.se., Petronis S; RISE Research Institutes of Sweden, Methodology, Textile and Medical Device, Brinellgatan 4, 50462 Borås, Sweden. Joakim.hakansson@ri.se., Krona A; RISE Research Institutes of Sweden, Agriculture and Food, Box 5401, 40229 Gothenburg, Sweden., Eriksson JS; TATAA Biocenter AB, Gothenburg, Sweden., Rosendahl J; RISE Research Institutes of Sweden, Methodology, Textile and Medical Device, Brinellgatan 4, 50462 Borås, Sweden. Joakim.hakansson@ri.se., Crisostomo V; Jesús Usón Minimally Invasive Surgery Centre, Cáceres 10004, Spain.; CIBER de Enfermedades Cardiovasculares, CIBER CV, Madrid 28029, Spain.; RICORS-TERAV Network, ISCIII, Madrid 28029, Spain., Sanchez-Margallo FM; Jesús Usón Minimally Invasive Surgery Centre, Cáceres 10004, Spain.; CIBER de Enfermedades Cardiovasculares, CIBER CV, Madrid 28029, Spain.; RICORS-TERAV Network, ISCIII, Madrid 28029, Spain., Baez-Diaz C; Jesús Usón Minimally Invasive Surgery Centre, Cáceres 10004, Spain.; CIBER de Enfermedades Cardiovasculares, CIBER CV, Madrid 28029, Spain.; RICORS-TERAV Network, ISCIII, Madrid 28029, Spain., Strehl R; VERIGRAFT AB, Arvid Wallgrensbacke 20, 41346, Göteborg, Sweden., Håkansson J; RISE Research Institutes of Sweden, Methodology, Textile and Medical Device, Brinellgatan 4, 50462 Borås, Sweden. Joakim.hakansson@ri.se.; Gothenburg University, Department of Laboratory Medicine, Institute of Biomedicine, Gothenburg, Sweden.

Publikováno v: Biomaterials science [Biomater Sci] 2023 May 30; Vol. 11 (11), pp. 3860-3877. Date of Electronic Publication: 2023 May 30.

Preclinical Evaluation of the Safety and Immunological Action of Allogeneic ADSC-Collagen Scaffolds in the Treatment of Chronic Ischemic Cardiomyopathy.

Autor: López-Díaz de Cerio A; Department of Cell Therapy and Hematology, Clínica Universidad de Navarra, 31008 Pamplona, Spain.; Instituto de Investigación Sanitaria de Navarra (IdiSNA), 31008 Pamplona, Spain., Perez-Estenaga I; Center for Applied Medical Research (CIMA), Regenerative Medicine Department, 31008 Pamplona, Spain., Inoges S; Department of Cell Therapy and Hematology, Clínica Universidad de Navarra, 31008 Pamplona, Spain.; Instituto de Investigación Sanitaria de Navarra (IdiSNA), 31008 Pamplona, Spain., Abizanda G; Instituto de Investigación Sanitaria de Navarra (IdiSNA), 31008 Pamplona, Spain.; Center for Applied Medical Research (CIMA), Regenerative Medicine Department, 31008 Pamplona, Spain., Gavira JJ; Instituto de Investigación Sanitaria de Navarra (IdiSNA), 31008 Pamplona, Spain.; Department of Cardiology, Clínica Universidad de Navarra, 31008 Pamplona, Spain., Larequi E; Center for Applied Medical Research (CIMA), Regenerative Medicine Department, 31008 Pamplona, Spain., Andreu E; Department of Cell Therapy and Hematology, Clínica Universidad de Navarra, 31008 Pamplona, Spain.; Instituto de Investigación Sanitaria de Navarra (IdiSNA), 31008 Pamplona, Spain., Rodriguez S; Center for Applied Medical Research (CIMA), Regenerative Medicine Department, 31008 Pamplona, Spain., Gil AG; Department of Pharmacology and Toxicology, University of Navarra, 31009 Pamplona, Spain., Crisostomo V; Jesús Usón Minimally Invasive Surgery Centre (CCMIJU), Ctra. N-521, Km. 41.8, 10071 Cáceres, Spain.; CIBERCV, Instituto de Salud Carlos III, 28026 Madrid, Spain., Sanchez-Margallo FM; Jesús Usón Minimally Invasive Surgery Centre (CCMIJU), Ctra. N-521, Km. 41.8, 10071 Cáceres, Spain.; CIBERCV, Instituto de Salud Carlos III, 28026 Madrid, Spain., Bermejo J; CIBERCV, Instituto de Salud Carlos III, 28026 Madrid, Spain.; Department of Cardiology, Hospital Gregorio Marañón and Instituto de Investigación Sanitaria Gregorio Marañón, 28007 Madrid, Spain.; Facultad de Medicina, Universidad Complutense de Madrid, 28040 Madrid, Spain., Jauregui B; Viscofan SA, 31192 Pamplona, Spain., Quintana L; Naturin Viscofan GmbH, 69469 Weinheim, Germany., Fernández-Avilés F; CIBERCV, Instituto de Salud Carlos III, 28026 Madrid, Spain.; Department of Cardiology, Hospital Gregorio Marañón and Instituto de Investigación Sanitaria Gregorio Marañón, 28007 Madrid, Spain.; Facultad de Medicina, Universidad Complutense de Madrid, 28040 Madrid, Spain., Pelacho B; Instituto de Investigación Sanitaria de Navarra (IdiSNA), 31008 Pamplona, Spain.; Center for Applied Medical Research (CIMA), Regenerative Medicine Department, 31008 Pamplona, Spain., Prósper F; Department of Cell Therapy and Hematology, Clínica Universidad de Navarra, 31008 Pamplona, Spain.; Instituto de Investigación Sanitaria de Navarra (IdiSNA), 31008 Pamplona, Spain.; Center for Applied Medical Research (CIMA), Regenerative Medicine Department, 31008 Pamplona, Spain.

Publikováno v: Pharmaceutics [Pharmaceutics] 2021 Aug 17; Vol. 13 (8). Date of Electronic Publication: 2021 Aug 17.